IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Abroad (travel likely)RecruitingPHASE2

Conditions

Lung Cancer (Non-Small Cell)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University,, Guangzhou, Guangdong, China
Contact: Study coordinator (Qing Zhou, PhD) · gzzhouqing@126.com · 020-83827812
Contact: Principal Investigator (Qing Zhou)
Chinese PLA General Hospital, Beijing, China
Contact: Study coordinator (Yi Hu) · huyi0401@aliyun.com · 010-68182255
Contact: Principal Investigator (Yi Hu)
The First People's Hospital of Foshan, Foshan, China
Contact: Study coordinator (Wei-Neng Feng) · fengweineng@163.com · 0757-83163168
Contact: Principal Investigator (Wei-Neng Feng)
The first affiliated hospital of nanchang university, Nanchang, China
Contact: Study coordinator (Long-Hua Sun) · ndyfy05715@ncu.edu.cn · 0791-88692748
Contact: Principal Investigator (Long-Hua Sun)
The Second Affiliated Hospital of Nanchang University, Nanchang, China
Contact: Study coordinator (An-Wen Liu) · liuanwen999@126.com · 0791-86120120
Contact: Principal Investigator (An-Wen Liu)
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
Contact: Study coordinator (Qi-Tao Yu) · yqt178@163.com · 0771-5331955
Contact: Principal Investigator (Qi-Tao Yu)
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Contact: Study coordinator (Jian Shi) · shijian6668@126.com · 0311-86095200
Contact: Principal Investigator (Jian Shi)

View source on ClinicalTrials.gov